• Save
Albumin in pediatric critical care
Upcoming SlideShare
Loading in...5

Like this? Share it with your network


Albumin in pediatric critical care



Role of Albumin in Critical Care and Intensive Care setting.

Role of Albumin in Critical Care and Intensive Care setting.



Total Views
Views on SlideShare
Embed Views



2 Embeds 10

http://www.slideee.com 9
http://www.linkedin.com 1



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • Although Hemoglobin is a far too important molecule, Albumin exceeds it by cool 50,000 results!!!
  • The lack of “albondin” in some anatomical compartments, such as the brain, accounts for the low concentration of this protein in the cerebrospinal fluid1
  • In this regard, it is evident how albumin concentration may be important when administering drugs with a high-binding affinity, especially during acute pathological processes usually characterised by hypoalbuminaemia. In these conditions, drug toxicity or even drug inefficiency may be observed33
  • Thus, although hypoalbuminaemia is very commonly observed in critically ill patients, the dilemma is whether this alteration may really have an impact on the outcome of such patients. In other words, the real question is whether the relationship between hypoalbuminaemia and mortality is a simple association or a cause-effect relation, and, if the latter is the case, what the best cure for hypoalbuminaemia is.
  • Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;135:149-64.
  • Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg 2003;237:319-34
  • The most commonly observed pathological alteration in albumin concentration in the critically ill is hypoalbuminaemia
  • In spite of no clear evidence from randomized clinical trials we may conclude in favor of a

Albumin in pediatric critical care Presentation Transcript

  • 1. Role of Albumin in PICU DR FARHANSHAIKH Consultant Pediatric Intensivist In-charge Quality and Accreditation Rainbow Children’s Hospital Hyderabad
  • 2. WHY ALBUMIN IS “HOT” TOPIC? • A search of word ALBUMIN on pubmed yields 199,905 results ! • Search word “Hemoglobin” yields 155311 results! • Almost 40% of all the publications on albumin have been concentrated in the last 10 years
  • 3. Physiology and pathophysiology of albumin in humans • Molecular weight of 66,500 Daltons, • Albumin is responsible for about 80% of the intravascular oncotic pressure. Weil MH, Henning RJ, Puri VK. Colloid oncotic pressure: clinical significance. Crit Care Med 1979;7:113-6
  • 4. • The liver produces albumin, which is immediately secreted into the intravascular space by the cells without being stored. • From the intravascular space, albumin passes into the interstitial space to different degrees and at different rates depending on the anatomical location, in a process called "transcapillary filtration”.
  • 5. • In regions where endothelium has large gaps, the filtration of albumin is passive • In regions where endothelium is nonfenestrated Albumin filtration is active, under the particular action of a specific receptor, i.e., “albondin”.
  • 6. Molecular structure of albumin Three main characteristics (i) cysteine residues (ii) domains I and II and (iii) imidazole residues.
  • 7. How Albumin Helps? The oncotic properties of this protein play a critical role in regulating volaemic status particularly during adverse clinical conditions where volaemia is very often altered.
  • 8. • Cysteine residues in position 34 expose a –SH radical group (thiol), which is one of the main extracellular antioxidants. • Moreover, –SH residues bind nitric oxide to form S-nitrous thiols, thereby neutralizing one of the most important mediators of pathological conditions mainly sepsis
  • 9. Albumin may also neutralize the vasodilating effect of nitric oxide, which is the most important mediator altering vascular tone during sepsis or other pathological conditions such as hepat-orenal syndrome
  • 10. Albumin domains I and II are responsible for the transport of the numerous molecules, both endogenous and exogenous, that are extensively carried by human albumin.
  • 11. • Finally, albumin has 16 histidine imidazole residues, which are responsible for the “buffer function” of albumin. • Having a pH of about 6.75, the residues may both give up or accept H+ from the environment depending on the surrounding pH, thereby acting as a buffer molecule.
  • 13. YEAR 1998
  • 14. This Cochrane report based on a meta-analysis suggested the potentially harmful effect of albumin administration as compared to other fluids for volume replacement
  • 15. The meta-analysis, included 32 clinical trials involving a total of 1,419 patients, and showed, among patients with surgery- or trauma-induced hypovolaemia, no differences in mortality between those treated with albumin and those treated with crystalloids.
  • 16. In fact, patients with burns who were treated with albumin appeared to have a higher mortality rate as compared to those treated with crystalloids.
  • 17. The authors concluded.. "There is no evidence that the administration of albumin reduces mortality in critically ill patients with hypovolemia, burns, hypoalbuminemia, but rather a strong indication that it increases mortality” This led to an extensive reduction of the use of albumin in some countries Use of Albumin in Intensive Care Units in the United Kingdom J. M. BROWN et al. Critical Care and Resuscitation 2001; 3: 19-21
  • 18. Meta-analysis published in 2001, concluding that ALBUMIN ADMINISTRATION WAS SAFE, although it had no effects on global mortality.
  • 19. A third meta-analysis, which included nine prospective, randomized clinical trials on critically ill patients with hypoalbuminaemia, was concluded and published in 2003.
  • 20. Meta-analysis regression analysis A statistically significant correlation was observed between the rate of complications and the plasma level of albumin
  • 21. The authors concluded : "Currently there is no reason for not administering albumin when clinically appropriate."
  • 22. • The first metanalysis appeared to be AGAINST • The second one was NEUTRAL and • The third one was IN FAVOUR of the clinical use of albumin.
  • 23. WHY THIS CONTROVERSY..?? • Many Heterogenous studies with heterogeneous patient selection • The point in time at which fluid was administered to patients enrolled in these trials could have been crucial.
  • 24. anti- oxidant paradox effect • A good anti-oxidant is a reducing agent. • Oxidative damage releases transition metals from damaged metallo-proteins. • By reducing these transition metals, an antioxidant administered after damage has started can create more reactive species which catalyse ROS formation.
  • 25. Higher doses of albumin, and Its Delayed administration, May not BE comparable with LOWER DOSES AND ITS early Administration Hypoalbuminemia in Acute Illness: Is There a Rationale for Intervention? A Meta-Analysis of Cohort Studies and Controlled Trials. Jean-Louis Vincent et al ANNALS OF SURGERY Vol. 237, No. 3, 319–334
  • 26. Study protocols also varied with regard to fluid volume administration: • some used fixed doses, • others targeted cardiovascular parameters or metabolic markers of perfusion and • others allowed clinical discretion.
  • 27. EVERY ALBUMIN IS NOT SAME!! Albumin from different batches of the same product contain molecules with a wide range of variable post-translational modifications including .. • glycosylation, • missing terminal amino acids and cysteinylation and nitrosilation of the free cysteine residue Bar-Or D, Bar-Or R, Rael LT et al. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med 2005;33:1638-41.
  • 28. • Some of these variations lead to a loss of oxidant-buffering capacity, and abolish the molecules’ ability to chelate free copper. • Thus clinical effects may vary and this can seriously affect the final outcome. • Genetically engineered recombinant Albumin may eliminate such variations and allow more predictable clinical outcomes. Hypoalbuminemia in Acute Illness: Is There a Rationale for Intervention? A Meta-Analysis of Cohort Studies and Controlled Trials. Jean-Louis Vincent et al ANNALS OF SURGERY Vol. 237, No. 3, 319–334
  • 29. The SAFE study
  • 30. The SAFE study 16 ICU in Australia and New Zealand conducted a prospective, randomized, double- blind study, the Saline vs. Albumin Evaluation (SAFE) study The study compared the effects of the infusion of 4% albumin and saline solution (0.9% NaCl) for volume replacement in critically ill patients with hypovolemia Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56
  • 31. About 7,000 patients were enrolled. Three predefined subgroups of patients with specific diseases i.e. • sepsis, • trauma and • acute respiratory distress syndrome.
  • 32. No difference in 28-day mortality, length of stay, or organ dysfunction was observed between the groups of patients receiving the two different treatment.
  • 33. Thus, clearly demonstrating that 4% albumin infusion for volume replacement in critically ill patients does not offer any advantage as compared to normal saline, or, in other words, that albumin administration is "safe". Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56
  • 34. Albumin may be as safe as Saline, but that does not mean Albumin is better ! Agreed.. However.. • The SAFE study was not designed to investigate possible beneficial effects of albumin • The amount of study fluid was relatively limited.
  • 35. The great contribution of the SAFE study came from the subgroup analysis performed • The patients with trauma, especially after head injury, treated with albumin tended to have a higher mortality rate (P = 0.06) • those with severe sepsis tended to show a better survival, although the difference did not reach statistical significance (P = 0.09).
  • 36. SAFE study, for the first time, turned the attention of researchers towards the possible crucial role of different categories of patients, when dealing with the type of fluid to be employed for volume replacement.
  • 37. Patients with traumatic brain injury A post- hoc follow-up of the patients with traumatic brain injury previously enrolled in the SAFE study, Higher mortality was observed in patients with severe traumatic brain injury, with mortality rates of 41.8% and 22.2% in patients treated with albumin or saline, respectively (p < 0.001)
  • 38. The authors, therefore, concluded that “critically ill patients with traumatic brain injury, fluid resuscitation with albumin was associated with higher mortality rates than was resuscitation with saline"
  • 39. Hypoalbuminemia Vs Mortality Many studies in children as well as adults have demonstrated strong association between hypoalbuminemia and mortality Powers KA, Kapus A, Khadaroo RG, et al. Twenty-five percent albumin prevents lung injury following shock/ resuscitation. Crit Care Med 2003;31:2355-63. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997;50:693-703. 38) Roberts I, Bunn F. Egg on their faces. The story of human albumin solution. Eval Health Prof 2002; 25:130-8.
  • 40. Year 2006 Dubois study Crit Care Med 2006;34:2536-40.
  • 41. This study investigated the hypothesis that correcting hypoalbuminaemia in critically ill patients in an attempt to maintain plasma albumin concentration within the normal range (greater than 3 g/dL) may have beneficial effects on organ function.
  • 42. In Dubois study, patients were randomized to receive 300 mL of 20% albumin solution on the first day after randomization and 200 mL/day if their plasma albumin concentration was lower than 3 g/dL in the treated group, or to receive no albumin infusion in the control group. Crit Care Med 2006;34:2536-40.
  • 43. The authors, concluded that "Albumin administration may improve organ function in hypoalbuminaemic critically ill patients" Crit Care Med 2006;34:2536-40.
  • 44. This study provided, for the first time, some evidence about the critical role of maintaining plasma albumin concentrations within a normal range, throughout the ICU admission, with a possible impact on organ function.
  • 45. Albumin Vs Artificial Colloids
  • 46. This systematic review includes the results of four recent randomized clinical trials of HES 130/0.38-0.45 comprising more than 3000 patients with sepsis
  • 47. The study showed Hydroxy Ethyl Starch increased… • the use of renal replacement therapy • transfusion with red blood cells, • Resulted in more serious adverse events inpatients with sepsis.
  • 48. The authors concluded that.. “It seems unlikely that hydroxyethyl starch provides overall clinical benefit for patients with sepsis”.
  • 49. Clinical indications of using Albumin Three important categories can be made: • Patients with traumatic brain injury, • Patients with peripheral oedema during their recovery phase, and • Patients with severe sepsis.
  • 50. Patients with traumatic brain injury Patients with an active brain injury due to cerebral trauma, albumin administration should be avoided, preferring other types of fluids, such as normal saline, for acute volume resuscitation.
  • 51. Patients with peripheral oedema during their recovery phase In using crystalloids for volume replacement, the most important disadvantage is .. • the greater amount of fluids to be infused in order to reach the same volume effect of albumin or other synthetic colloids • a consequent increased risk of peripheral oedema and weight gain.
  • 52. Artificial colloids • Not found to be beneficial in sepsis • May cause coagulopathy, because of absorption of the factor VII/von Willebrand factor complex, • May lead to an increased risk of developing acute renal failure. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-7.
  • 53. THEORATICALLY… • During Acute phase , due to leaky capillaries even Albumin can leak out of the blood vessels but Albumin leaks slower than crystalloids thus reducing overall fluid required for resuscitation. (e.g. In Dengue Shock ) • During “recovery phase” as the capillaries stabilize, and Albumin will hold on intravascularly and improve the hemodynamics.
  • 54. • Unfortunately, no clear evidence from randomized clinical trials or other forms of large studies are currently available in this regard. • However, the soundness of the biological and pathophysiological rationale may at least partially justify such an indication for albumin administration.
  • 55. Lack of evidence may not necessarily exclude the possible beneficial effect
  • 56. In spite of no clear evidence from randomized clinical trials Albumin can be considered useful in patients with.. • marked hypoalbuminaemia, • peripheral edema, and • in serious need of water elimination, especially in their recovery phase after acute volume replacement. (Severe edema in Nephrotic syndrome, Post Cardio Pulmonary Bypass targetting Sr Albumin > 2.5gm% by Albumin transfusion and Diuretics)
  • 57. The ALBIOS Study (ALBumin Italian Outcome Sepsis) • Recently completed recruiting 1,818 patients fulfilling criteria for severe sepsis or septic shock. • All patients were resuscitated with crystalloids according to early goal-directed therapy protocols. Gattinoni L, Caironi P. The AlbIOS Study. Newsletter 36. http:// www.negrisud.it/albios/news/newsletter_albios_36.pdf Accessed 28 March 2012.
  • 58. • In addition, the intervention group received 300 mL 20% HAS on day 1 and further daily infusions to maintain serum albumin at or above 3 g/dL for the next 27 days. • The primary outcome was originally 28-day mortality, although this has been extended to 90 days.
  • 59. • In patients with sepsis albumin infusion compared to crystalloids alone provided hemodynamic advantages, and more favorable fluid balance without survival benefits. • In patients with septic shock, hemodynamic fluid balance advantages were greater than in general population and, in addition, these patients survived significantly more at 90 days.
  • 60. CONCLUSION Apart from its oncotic properties, albumin may be useful in critical care through its secondary functions, such as.. • The modulating action on nitric oxide metabolism • free radical production • its buffer effect in the acid-base equilibrium, • its action as a transporter of many different substances and drugs
  • 61. Patients with severe sepsis Although Albumin can leak through capillaries in early shock but it will leak slower than crystalloids, hence it can still be used during acute shock state to reduce overall fluid requirement. During later stages, it will be beneficial in maintaining oncotic pressure, fluid shifts.
  • 62. Albumin may have a beneficial impact.. • In patients with severe hypoalbuminaemia and peripheral oedema • During the recovery phase after acute volume replacement • On the elimination of the excessive accumulated volume.